bpc 157 vs nad+ Longevity Bundle (NAD+ & BPC-157 / TB-500) bpc 157 transdermal patches NAD+

Because oral and injectable delivery methods may differ significantly in absorption, equivalent dosing is not always a one-to-one conversion

A warm thank you to all co-authors and collaborators, Asger Bihlet, Yves Henrotin, Francois Rieger, Olivier Godeaux, MD, MPH, Helene Rovsin, Peter Alexandersen, Edith Min Chu Lou for their dedication throughout this demanding but essential process

Who Should Consider Avoiding BPC-157 Despite the overall reassuring safety profile, certain populations should strongly consider avoiding BPC-157 given the theoretical concerns about angiogenesis and cancer

If batch preparation is necessary for large studies, use low-retention syringes and refrigerate filled syringes at 28C, using them within 12 hours to minimize peptide loss